A clinical-stage TechBio company operating an AI-native drug-discovery platform across biology, chemistry and development.
Research candidate, not an investment rating. Identity and classification reflect a bounded evidence snapshot observed Jul 26, 2026.
Period ended Mar 31, 2026 · filed May 6, 2026
Period ended Dec 31, 2025 · filed Feb 25, 2026
Values are issuer-filed XBRL facts retrieved from SEC EDGAR. Missing concepts remain Unknown; non-GAAP values are not substituted.
AI roles are presented as source-anchored research interpretations. The document stream is regulator-primary, but a filing’s existence does not prove the claims contained inside it.
Role evidence, not a proprietary investment score
AI is central to the issuer’s described operating identity and current product portfolio.
The annual filing identifies the Recursion OS and its integration of proprietary data, machine learning and automated experimentation.
The issuer supplies data, evaluation or engineering capabilities used in AI development.
Current issuer results describe active discovery programs, partnerships and platform milestones without proving clinical success.
The annual filing identifies the Recursion OS and its integration of proprietary data, machine learning and automated experimentation.
Current issuer results describe active discovery programs, partnerships and platform milestones without proving clinical success.
These sources support the issuer/listing and AI-exposure assessment. First-party evidence proves attribution—not independent truth.